Presentation Material (Conference on Q1 FY2026 Financial Results)
Filed with TSE · · 29 pages · English
Summary by 6ix AI
It reports on revenue, gross profit, and research and development expenses, highlighting significant growth in the U.S. market. Overall, the company maintains its forecasts for the fiscal year despite some challenges in specific markets.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Sumitomo Pharma Co.Ltd. on 6ix
In the deck
Story so far
Earlier from Sumitomo Pharma Co.Ltd
- Matters Concerning Controlling Shareholders, Etc.
- Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026
- Sumitomo Pharma Announces Organizational Change, Change in the Responsibilities of Executive Officer, and Personnel Change
- New Data from Sumitomo Pharma America at AUA 2026 Highlight Efficacy of Vibegron in Men Aged 75 and Older with Overactive Bladder and BPH
- May 13, 2026 Conference on FY2025 Financial Results transcript（PDF/5,711KB）
Later from Sumitomo Pharma Co.Ltd
- Regarding a Report Concerning Sumitomo Pharma
- Additional Explanation Regarding the Report “Sumitomo Chemical and Sumitomo Pharmaceutical: The 116 billion yen Swiss Shuffle”
- Regarding a Report Concerning Sumitomo Pharma (The Company's Views on the GCR August 7 Report)
- Notice Concerning Gain on Return of Retirement Benefit Trust (Extraordinary Income) Recorded in the Company’s Non-Consolidated Financial Statements
- Presentation Material (Conference on Q2 FY2026 Financial Results
Follow Sumitomo Pharma Co.Ltd into a list and get an email when it puts out news.
Follow Sumitomo Pharma Co.Ltd